爵士制药 JAZZ 深 沪
等待开盘 05-19 09:30:00 美东时间
229.63
+0.860
+0.38%
华盛通- 最 高231.43
- 今 开228.96
- 成交量 23.73万股
- 最 低 228.13
- 昨 收 228.77
- 总市值 1440.76万
- 52周最高 235.00
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 105.00
- 委 比 -81.82%
- 总股本 6.27万
- 历史最高 235.00
- 量 比 0.46
- 振 幅 1.44%
- 历史最低 31.87
- 每 手 1
- 风险率 33.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
Zymeworks Inc. announced a $125 million share repurchase program for 2026, replacing its 2025 program under which it repurchased 4,197,553 shares for $102.3 million. CEO Kenneth Galbraith emphasized disciplined capital allocation and long-term value creation while preserving flexibility for R&D and strategic opportunities. The company had approximately 73.0 million outstanding shares as of May 13, 2026. The program will be funded by the company's...
05-14 20:05
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. announced that its management will participate in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum on May 20, the TD Cowen 7th Annual Oncology Innovation Summit on May 27, and the 2026 Jefferies Global Healthcare Conference on June 3. The company focuses on developing innovative biotherapeutics for challenging diseases like cancer, inflammation, and autoimmune conditions, leveraging its proprieta...
05-13 10:00
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology reported positive data from its Phase 1b/2 trial of evorpacept combined with zanidatamab in HER2-positive breast cancer patients, showing durable responses, particularly in those with high CD47 expression. The company also highlighted progress in its ASPEN-09-Breast Phase 2 trial and ALX2004 Phase 1 trial. Additionally, ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer, strengthening its leadership team. T...
05-08 12:00
Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks
Foreign healthcare stocks are earning some of the market's strongest Quant conviction right now, with the top five names on this ranking all carrying scores above 4.19, a cluster of high-conviction si...
05-07 19:50
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $234
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $225 to $234.
05-06 23:16
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, Lumentum Holdings and TransDigm Group, on Wednesday. HIGHLIGHTS * Advanced Micro Devices AMD.O : Ev
05-06 15:13
电话会总结 ｜ Jazz(JAZZ)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Jazz Pharmaceuticals 2026年第一季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **总营收表现：** 2026年第一季度总营收达到11亿美元，同比增长超过19%，创下公司历史最高第一季度营收纪录。主要增长驱动力来自Xywav、Epidiolex、Midevo和Zepzelca等核心产品。 **各产品线营收：** - Xywav净销售额4.08亿美元，同比增长18% - Epidiolex净销售额2.50亿美元，同比增长15% - Midevo净销售额4,100万美元（2025年8月上市以来） - Zepze
05-06 12:33
Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
On Tuesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) discussed first-quarter financia...
05-06 05:52
财报速睇 | 爵士制药 2026财年Q1营收10.69亿美元，同比增长19.0%；归母净利润2.93亿美元，扭亏为盈
华盛资讯5月6日讯，爵士制药公布2026财年Q1业绩，公司Q1营收10.69亿美元，同比增长19.0%，归母净利润2.93亿美元，扭亏为盈。
05-06 05:23
